seladelpar

02/01/2021 - "ENHANCE: Safety and Efficacy of Seladelpar in Patients With Primary Biliary Cholangitis-A Phase 3, International, Randomized, Placebo-Controlled Study."
01/01/2023 - "Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study."
01/01/2022 - "A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis."
10/30/2023 - "Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis."
11/01/2022 - "Reply to: "Seladelpar in patients with primary biliary cholangitis: Need for a closer look!""

01/01/2022 - "This open-label, uncontrolled phase 2 study in PBC patients evaluated the effects of 1-year of seladelpar treatment on measures of pruritus and quality of life. "
01/01/2023 - "Seladelpar 10 mg significantly reduced mean pruritus NRS versus placebo [10 mg: -3.14 ( p =0.02); placebo: -1.55]. "
01/01/2022 - "Seladelpar appeared safe and well tolerated and was not associated with any increase in pruritus. "
01/01/2023 - "Patients with primary biliary cholangitis (PBC) with inadequate response or intolerance to UDCA who were treated with seladelpar 10 mg had significant improvements in liver biochemistry and pruritus. "
01/01/2022 - "Self-reported experiences of 101 PBC patients were collected at baseline and after 1 year of seladelpar treatment using the pruritus visual analog scale (VAS), 5D-itch scale, and PBC-40 questionnaires along with bile acid profiles. "

10/30/2023 - "In those with elevated bilirubin at baseline, 43% achieved normalisation at year 2. Seladelpar was safe, and markedly improved biochemical markers of cholestasis and liver injury in patients with PBC. "
01/01/2022 - "Seladelpar demonstrated robust, dose-dependent, clinically significant, and durable improvements in biochemical markers of cholestasis and inflammation in patients with PBC at risk of disease progression. "

01/01/2022 - "Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis."

10/01/2022 - "In 2019, CymaBay Therapeutics halted clinical trials of seladelpar (a PPARδ agonist) because initial end-of-treatment liver biopsies of patients with non-alcoholic steatohepatitis (NASH) showed concerning features of portal inflammation with plasma cells, interface hepatitis and focal bile duct abnormalities. "
11/28/2023 - "Seladelpar combined with complementary therapies improves fibrosis, inflammation and liver injury in a mouse model of nonalcoholic steatohepatitis."
01/01/2022 - "Seladelpar demonstrated robust, dose-dependent, clinically significant, and durable improvements in biochemical markers of cholestasis and inflammation in patients with PBC at risk of disease progression. "